Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Posts 12-Percent Revenue Gain in Q2, Ups '06 Guidance

NEW YORK (GenomeWeb News) – Harvard Bioscience today reported that improved sales in the second quarter helped recude net loss by more than 98 percent.
 
Receipts for the three months ended June 30 increased 12 percent to $18 million from $16 million year over year as a result of improved product mix and higher margins on new product introductions, Harvard Bio said.
 
R&D costs increased 10 percent to $773,000 from $704,000 from the comparable quarter a year ago.
 
The company said net loss shrank to $324,000 from $23.7 million during the comparable period last year. The company said approximately $300,000 in restructuring charges was recorded during the second quarter of 2005.
 
Harvard Bioscience said it had around $8.2 million in cash and cash equivalents as of June 30.
 
The company raised its revenue guidance for the full year 2006 and now expects to generate between $72 million and $73 million instead of between $70 million and $72 million.
 
Strong market demand and the acquisition of the Anthos product line is expected to drive the increase, said Chane Graziano, chief executive officer, in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.